Loading...
Please wait, while we are loading the content...
Similar Documents
Triple-negative Phenotype in Metastatic Breast Cancer — Where Do We Stand in Terms of Treatment?
| Content Provider | Semantic Scholar |
|---|---|
| Author | Biganzoli, Laura Claudino, Wederson M. Leo, Angelo Di |
| Copyright Year | 2007 |
| Abstract | Treatment of breast cancer has come a long way. The recent elucidation of distinctive molecular breast cancer subtypes through gene expression profiling has shed light on the heterogeneous clinical behaviour and outcomes of seemingly alike morphological breast cancers.1 This information could be translated in the scenario of clinical trials and clinical practice as a streamlined approach for targeting specific molecular defects on cancer cells that are thought to drive tumour cell progression. A subpopulation emerging as having particularly poor prognosis is those patients who have disease that is receptor-negative for oestrogen, progestin and human epidermal growth factor receptor 2 (HER2 or HER2neu – triple-negative disease). The lack of these targets obviates any consideration regarding use of hormone therapies or HER2targeted agents. |
| Starting Page | 52 |
| Ending Page | 52 |
| Page Count | 1 |
| File Format | PDF HTM / HTML |
| DOI | 10.17925/EOH.2007.0.2.52 |
| Alternate Webpage(s) | http://www.touchoncology.com/system/files/private/articles/18225/pdf/biganzoli.pdf |
| Alternate Webpage(s) | https://doi.org/10.17925/EOH.2007.0.2.52 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
